Business Context and Reporting Period
Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2024
Business Overview: A pre-revenue, clinical-stage medical device company developing a catheter-based microchip-enabled array for sensing and treating disorders of the peripheral nervous system. The company is currently focused on pain management for pancreatic cancer.
Corporate Actions: Completed a 1-for-20 reverse stock split effective October 24, 2024. Closed a public offering in November 2024 raising approximately $10.0 million in gross proceeds.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2024 | Nine Months Ended Dec 31, 2024 | As of Dec 31, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,712) | $(8,219) | N/A |
| Operating Expenses | $2,747 | $8,336 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $11,823 |
| Working Capital | N/A | N/A | $9,707 |
| Short-Term Debt (Convertible Notes) | N/A | N/A | $1,132 |
| Accumulated Deficit | N/A | N/A | $(47,187) |
Note: All financial figures are in thousands, except per share data. The company reported no revenue for the periods presented.
Material Changes vs. Prior Period
- Operating Expenses: For the nine months ended Dec 31, 2024, total operating expenses decreased by 13% ($1.3 million) compared to the prior year period. This decrease was primarily driven by the absence of a $4.6 million warrant expense related to a termination agreement recorded in the prior year. However, General and Administrative (G&A) expenses increased by 46% and Research and Development (R&D) expenses increased by 108% due to expanded management teams and clinical trial costs.
- Net Loss: Net loss for the nine months ended Dec 31, 2024, was $8.2 million, a decrease of $1.8 million compared to the $10.0 million loss in the same period of 2023, largely attributable to the non-recurring warrant expense in the prior year.
- Liquidity: Cash and cash equivalents increased from $8.6 million at March 31, 2024, to $11.8 million at December 31, 2024, following the November 2024 equity offering.
- Debt Structure: As of December 31, 2024, the company reclassified remaining convertible notes from long-term to short-term liabilities. Approximately $1.3 million in principal remains outstanding from the 2023 Bridge Offering, with a net carrying amount of $1.1 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates current cash resources are sufficient to fund operations into, but not beyond, the first calendar quarter of 2026. The company anticipates needing an additional $30 million to $35 million to reach commercialization of its first indication.
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern within one year of the report date due to recurring losses and the need for additional financing.
- Capital Raising: The company closed a public offering in November 2024 consisting of Common Units and Pre-Funded Units, raising approximately $10.0 million in gross proceeds. Net cash proceeds were approximately $9.0 million.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, citing a lack of segregation of duties and limited staffing. Management is implementing remediation plans, including hiring experienced staff and utilizing consultants.
- Reverse Stock Split: A 1-for-20 reverse stock split was effective in October 2024. The company is currently investigating a request from the DTCC to issue approximately 271,846 shares for fractional share rounding, which could result in dilution if validated.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2026" liquidity estimate given the high burn rate and potential for increased clinical trial costs.
- Fractional Shares Liability: Monitor the outcome of the inquiry regarding the 271,846 shares requested by DTCC for fractional rounding; issuance would cause immediate dilution.
- Internal Controls: Assess the progress of remediation efforts for the material weaknesses in internal controls, specifically regarding segregation of duties.
- Debt Conversion: Review the terms of the remaining $1.3 million convertible notes and the potential for future dilution upon conversion or maturity.
- Regulatory Milestones: Track progress on the first-in-human demonstration of transvascular ablation and subsequent pivotal clinical trials, as revenue generation is entirely dependent on regulatory clearance.